FRI technology showed substantial and homogeneous vasodilation during phase one research for new PAH medication.
Pulmonary Hypertension (PH) patients need more treatment options, and it seems the Merck’s MK5475 inhaled drug is quite promising! FLUIDDA’s FRI technology showed substantial and homogeneous vasodilation throughout the lung associated with an improvement in hemodynamics as measured by right heart catheterization.
The Holy Grail in the treatment of Pulmonary Arterial Hypertension is to demonstrate remodeling of the abnormal blood vessel wall. FLUIDDA has taken a major step towards reaching this goal by developing a proprietary algorithm that measures blood vessel wall thickness and volume from a simple CT scan.
Categorised in: Articles / February 2, 2023 1:12 pm /Tags: FRI, PAH